Fulgent Genetics Stock Profit Margin
FLGT Stock | USD 20.13 0.10 0.49% |
Fulgent Genetics fundamentals help investors to digest information that contributes to Fulgent Genetics' financial success or failures. It also enables traders to predict the movement of Fulgent Stock. The fundamental analysis module provides a way to measure Fulgent Genetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fulgent Genetics stock.
Fulgent |
Fulgent Genetics Company Profit Margin Analysis
Fulgent Genetics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Fulgent Genetics Profit Margin | (0.59) % |
Most of Fulgent Genetics' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fulgent Genetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition |
Based on the latest financial disclosure, Fulgent Genetics has a Profit Margin of -0.5939%. This is 94.7% lower than that of the Health Care Providers & Services sector and 94.88% lower than that of the Health Care industry. The profit margin for all United States stocks is 53.24% lower than that of the firm.
Fulgent Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fulgent Genetics' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fulgent Genetics could also be used in its relative valuation, which is a method of valuing Fulgent Genetics by comparing valuation metrics of similar companies.Fulgent Genetics is currently under evaluation in profit margin category among its peers.
Fulgent Fundamentals
Return On Equity | -0.14 | ||||
Return On Asset | -0.0415 | ||||
Profit Margin | (0.59) % | ||||
Operating Margin | (0.24) % | ||||
Current Valuation | 410.47 M | ||||
Shares Outstanding | 30.59 M | ||||
Shares Owned By Insiders | 32.30 % | ||||
Shares Owned By Institutions | 54.29 % | ||||
Number Of Shares Shorted | 579.04 K | ||||
Price To Earning | 3.95 X | ||||
Price To Book | 0.54 X | ||||
Price To Sales | 2.31 X | ||||
Revenue | 289.21 M | ||||
Gross Profit | 366.9 M | ||||
EBITDA | (46.55 M) | ||||
Net Income | (167.82 M) | ||||
Cash And Equivalents | 515.4 M | ||||
Cash Per Share | 17.03 X | ||||
Total Debt | 15.25 M | ||||
Debt To Equity | 0.03 % | ||||
Current Ratio | 5.29 X | ||||
Book Value Per Share | 37.28 X | ||||
Cash Flow From Operations | 27 M | ||||
Short Ratio | 2.64 X | ||||
Earnings Per Share | (5.52) X | ||||
Price To Earnings To Growth | 1.32 X | ||||
Target Price | 27.67 | ||||
Number Of Employees | 1.18 K | ||||
Beta | 1.51 | ||||
Market Capitalization | 641.41 M | ||||
Total Asset | 1.24 B | ||||
Retained Earnings | 633.17 M | ||||
Working Capital | 434.83 M | ||||
Current Asset | 2.93 M | ||||
Current Liabilities | 686 K | ||||
Net Asset | 1.24 B |
About Fulgent Genetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fulgent Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulgent Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulgent Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.